 0 Table of Contents |
  1 Home |
  2 Objetives |
  3 Scope |
  4 How to complete IG |
  5 Transaction |
  6 Uses cases and actors |
  7 Artifacts |
   7.1 ESAVI Questionnaire Response |
   7.2 Coding Systems |
   7.3 Country Codes |
   7.4 COVID-19 Infection Confirmation Modes |
   7.5 Identification of Pharmaceutical Forms |
   7.6 MedDRA Code of the Reported Adverse Event |
   7.7 MEDDRA Codes Complications in Pregnancy ESAVI |
   7.8 MedDRA codes to represent previous diseases in an ESAVI-PAHO |
   7.9 Medication Administration Routes |
   7.10 Medication Code |
   7.11 Naranjo Causality Classification |
   7.12 Non-WHODrug Vaccine Code |
   7.13 Other Adverse Event Codes |
   7.14 Other ESAVI Pregnancy Complications Codes |
   7.15 Outcomes After ESAVI |
   7.16 PAHO Codes for Addresses |
   7.17 Pregnancy Complications |
   7.18 Previous illnesses in an ESAVI-PAHO |
   7.19 Previous Vaccine Verification Modes |
   7.20 Simple Answers |
   7.21 Type of Causality Classification Method |
   7.22 Type of Notifying Professional |
   7.23 Vaccine Manufacturers |
   7.24 WHO-AEFI causality classification |
   7.25 WHO-UMC Causality Classification |
   7.26 WHODrug code for the vaccine |
   7.27 Coding Systems |
   7.28 Country Codes |
   7.29 Infection Confirmation Mode |
   7.30 Naranjo Causality Classification |
   7.31 Outcomes After ESAVI |
   7.32 PAHO Codes for Addresses |
   7.33 Pregnancy Complications |
   7.34 Prior Vaccination Verification Mode |
   7.35 Simple Answers |
   7.36 Type of Causality Classification Method |
   7.37 Type of Notifying Professional |
   7.38 Vaccine Manufacturer |
   7.39 WHO-AEFI causality classification |
   7.40 WHO-UMC Causality Classification |
   7.41 ejDosNuevo |
   7.42 ejTresNuevo |
   7.43 ejUnoNuevo |
   7.44 ESAVI Questionnaire |
  8 Mappings |
  9 Terminologies |
  10 Downloads |
  11 Generalities |
  12 Considerations |
  13 Operations |
  14 Security |